Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin + BR in R/R DLBCL (China)
NCT04236141Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Jul 2020; status: terminated.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04236141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236141.